Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

Schneider D, Xiong Y, Wu D, Nӧlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ.

J Immunother Cancer. 2017 May 16;5:42. doi: 10.1186/s40425-017-0246-1. eCollection 2017.

2.

Reference Standards for Gene and Cell Therapy Products.

Dropulić B.

Mol Ther. 2017 Jun 7;25(6):1259-1260. doi: 10.1016/j.ymthe.2017.05.002. Epub 2017 May 11. No abstract available.

PMID:
28502471
3.

Towards a commercial process for the manufacture of genetically modified T cells for therapy.

Kaiser AD, Assenmacher M, Schröder B, Meyer M, Orentas R, Bethke U, Dropulic B.

Cancer Gene Ther. 2015 Mar;22(2):72-8. doi: 10.1038/cgt.2014.78. Epub 2015 Jan 23. Review.

4.

Rapid generation of stable cell lines expressing high levels of erythropoietin, factor VIII, and an antihuman CD20 antibody using lentiviral vectors.

Baranyi L, Doering CB, Denning G, Gautney RE, Harris KT, Spencer HT, Roy A, Zayed H, Dropulic B.

Hum Gene Ther Methods. 2013 Aug;24(4):214-27. doi: 10.1089/hgtb.2013.002.

PMID:
23879627
5.

Lentiviral vector-mediated genetic modification of cell substrates for the manufacture of proteins and other biologics.

Baranyi L, Roy A, Embree HD, Dropulic B.

PDA J Pharm Sci Technol. 2010 Sep-Oct;64(5):379-85.

PMID:
21502041
6.

Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research.

Dropulić B.

Hum Gene Ther. 2011 Jun;22(6):649-57. doi: 10.1089/hum.2011.058. Epub 2011 May 19. Review.

PMID:
21486177
7.

Supplemental Content

Loading ...
Support Center